Abstract 5314
Background
Spiritual distress is prevalent in advanced disease, but often neglected, resulting in unnecessary suffering. Religion and/or spirituality have increasingly been recognized as key elements in patients’ experience of advanced illness. This study aims to explore spiritual care needs, experiences, preferences and examine the association between religious coping and quality of life among patients with advanced cancer.
Methods
Structured interviews were conducted with 135 patients in advanced cancer patients and their primary informal caregivers. Patients completed measures of QOL (McGill QOL questionnaire), religious coping (Brief Measure of Religious Coping [RCOPE] and Multidimensional Measure of Religion/ Spirituality), self-efficacy (General Self-Efficacy Scale), and sociodemographic variables. Both positive and negative religious coping and multiple dimensions of QOL (physical, physical symptom, psychological, existential, and support) were studied.
Results
The median age of the population was 60.2 years and majority of the subjects were Hindus. The study revealed greater use of positive religious coping was associated with better overall QOL as well as higher scores on the existential and support QOL dimensions and was also related to more physical symptoms. However, greater use of negative religious coping was related to poorer overall QOL. Most patients believed it was important for health care professionals to consider patient spiritual concerns within the medical setting. Spiritual care was reportedly lacking, primarily due to staff members’ de-prioritisation and lack of time.
Conclusions
This study demonstrates that spiritual concerns are common among advanced cancer patients, and that they are associated with poorer psychological well-being. Spiritual care is an essential but neglected component of care, according to patients and their caregivers across a range of countries. The findings of the present study support the relationship between spirituality and health outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Vibhay Pareek.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2459 - Does bevacizumab increase joint pain ? Preliminary results of BEVARTHRALGIA Study
Presenter: Vauleon Enora
Session: Poster Display session 1
Resources:
Abstract
4913 - Prostatic cancer androgen deprivation therapy and bone health in carcinoma prostate.
Presenter: Gouri Shankar Bhattacharyya
Session: Poster Display session 1
Resources:
Abstract
1352 - Patterns of care for patients with metastatic bone disease in solid tumors – a cross-sectional study (SAKK 95/16)
Presenter: Michael Mark
Session: Poster Display session 1
Resources:
Abstract
6002 - Infection-Related Mortality in Different Types of Cancers
Presenter: Mohamed Gouda
Session: Poster Display session 1
Resources:
Abstract
5643 - Survival Trends in Critically ill Oncology Patients: impact of patient’s eligibility to post-ICU chemotherapy
Presenter: Edith Borcoman
Session: Poster Display session 1
Resources:
Abstract
3097 - Development and validation of a multivariable prediction model for 6-month mortality in older cancer patients: the GeriAtrIc-Tumor Score of PrEdiction for Early Death (GAIT SPEED)
Presenter: Angeli Angeli
Session: Poster Display session 1
Resources:
Abstract
856 - A Longitudinal Tracking and Quantitative Assessment of Paclitaxel-Induced Peripheral Neurotoxicity
Presenter: Ayumu Matsuoka
Session: Poster Display session 1
Resources:
Abstract
1662 - Efficiency of controlled cryotherapy in prevention of chemotherapy induced peripheral neuropathy (CIPN)
Presenter: Trudi Schaper
Session: Poster Display session 1
Resources:
Abstract
2766 - The Validity of Evaluations for Chemotherapy-Induced Peripheral Neuropathy (CIPN)
Presenter: Teppei Yamada
Session: Poster Display session 1
Resources:
Abstract
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract